News
-
-
COMMUNIQUÉ DE PRESSE
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2025 financial results and provides corporate update, highlighting vidofludimus calcium's therapeutic potential in multiple sclerosis. Phase 3 ENSURE trial data expected by 2026 -
-
-
-
-
-
-
-